Pre-clinical research conducted primarily in animal models has studied its potential roles in supporting the GI environment, gut barrier function, and inflammatory responses in the GI tract
This knowledge gap represents a major challenge for therapeutic strategies aimed at selectively targeting UPR signaling in cancer cells without inducing unacceptable toxicity in normal tissues
The 9mg dose option The phase 3 TRIUMPH trials introduced a 9mg maintenance dose that was not tested in phase 2
Prevents glutathione depletion within liver cells, supporting detoxification and protecting cells from free radical activity
Not just chemistry, but biology, precision design, and regulatory depth are now becoming essential to compete in this space." Hari Kiran Chereddi, MD & CEO, HRV Pharma and NHG Pharma GLP-1 Patent Expiry Timeline and Market Dynamics The market opportunity is defined by several critical factors: Patent Expiration: Semaglutide's key patents expire globally by early 2026 Market Growth: Demand for obesity and diabetes treatments growing 12-14% year-over-year Healthcare Savings: Indian companies can save global healthcare systems billions through cost-effective alternatives Regulatory Access: Opportunities to develop biosimilars or complex generics for US and EU markets Beyond Cost Competition: Value-Based Differentiation The competitive landscape for GLP-1 drugs extends beyond traditional cost advantages that have historically defined Indian pharmaceutical success
It activates the Nrf2 pathway, a master regulator that upregulates multiple antioxidant enzymes simultaneously, creating a comprehensive antioxidant response
&srotate=0)
